CD11c+ and IRF8+ cell densities in rectal cancer biopsies predict outcomes of neoadjuvant chemoradiotherapy
Approximately 20% of locally advanced rectal cancer (LARC) patients treated preoperatively with chemoradiotherapy (CRT) achieve pathologically confirmed complete regression. However, there are no clinically implemented biomarkers measurable in biopsies that are predictive of tumor regression. Here,...
Saved in:
| Main Authors: | Benita C. Y. Tse, Sarah Bergamin, Pascal Steffen, George Hruby, Nick Pavlakis, Stephen J. Clarke, Justin Evans, Alexander Engel, Andrew Kneebone, Mark P. Molloy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2238506 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant chemoradiotherapy in combined treatment of patients with rectal cancer
by: N. A. Maistrenko, et al.
Published: (2017-08-01) -
Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
by: Masaaki Nishi, et al.
Published: (2025-01-01) -
Response Assessment after Neoadjuvant Chemoradiotherapy in Rectal Cancer
by: Anuradha Chandramohan, et al.
Published: (2025-05-01) -
The Influence of Neoadjuvant Chemoradiotherapy on Muscle Mass in Patients with Rectal Cancer
by: Gregory Simpson, et al.
Published: (2019-07-01) -
Understanding and considerations of radiation-induced rectal and anal injury after neoadjuvant chemoradiotherapy for rectal cancer
by: Zhu Xiaoming, et al.
Published: (2023-10-01)